Cambridge, United States
Garuda Therapeutics, founded in 2021, is a rapidly evolving company in the Biotechnology and Life Sciences sectors. Headquartered in the United States, the company focuses on developing "off-the-shelf, long-term durable blood stem cell therapies" to eliminate reliance on donor or patient cells for blood stem cell transplants.
Their proprietary platform aims to provide HLA-compatible, transgene-free blood stem cell therapies. This innovation promises to offer potentially curative solutions for over 120 diseases, similar to traditional bone marrow transplants. This capability positions Garuda Therapeutics as a frontrunner in providing broader patient access to consistent, reliable treatments.
In a significant milestone, Garuda secured a $62.00M Series B investment as of 07 February 2023. Key investors include OrbiMed, Aisling Capital, Alexandria Venture Investments, Northpond Ventures, Sectoral Asset Management, Cormorant Asset Management, and Mass General Brigham Ventures, reflecting strong confidence in the company's potential and innovative approach.
